<DOC>
	<DOCNO>NCT00303628</DOCNO>
	<brief_summary>Drugs use chemotherapy , oxaliplatin , leucovorin , fluorouracil , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving one drug ( combination chemotherapy ) together bevacizumab surgery may kill tumor cell remain surgery . It yet know whether oxaliplatin , leucovorin , fluorouracil effective without bevacizumab treat rectal cancer . This randomized phase III trial study combination chemotherapy see well work without bevacizumab treat patient surgery stage II stage III rectal cancer .</brief_summary>
	<brief_title>Postoperative Chemotherapy With Without Bevacizumab Patients With Stage II III Rectal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare overall survival patient undergone prior surgery neoadjuvant chemoradiotherapy clinical stage II III rectal cancer treat adjuvant oxaliplatin , leucovorin calcium , fluorouracil v without bevacizumab . SECONDARY OBJECTIVES : I . Evaluate tolerance treatment , pattern failure , disease-free survival patient treat regimens EXPLORATORY OBJECTIVES : I. Assess long-term rectal function use Patient Bowel Function/Uniscale questionnaire Functional Assessment Cancer ( FACT ) -Diarrhea subscale patient treat regimen . II . Validate FACT-Diarrhea subscale . III . Assess long-term symptom oxaliplatin-related neurotoxicity use FACT/Gynecologic Oncology Group ( GOG ) -Neurotoxicity subscale patient treat regimen . IV . Correlate TS , DPD TP expression ( key target fluorouracil ) ; retention chromosome 18q allele microsatellite instability ( MSI ) TGFÎ²1RII mutation ( marker fluorouracil efficacy ) ; ERCC1 , ERCC2 , XPF expression ( participant repair adduct oxaliplatin ) ; p53 gene mutation possibly molecular marker pertinent vascular endothelial growth factor tumor tissue specimens treatment efficacy patient . V. Correlate tumor molecular prognostic marker ( chromosome 18q allelic loss MSI ) survival patient treat regimen . OUTLINE : This randomize study . Patients stratify accord Eastern Cooperative Oncology Group ( ECOG ) performance status ( 0 vs 1 ) , clinical staging ( high risk [ T3 , N+ , M0 T4 , N , M0 ] vs low risk [ T1-2 , N+ , M0 T3 , N0 , M0 ] ) , prior pre-operative oxaliplatin ( yes v ) , prior radiotherapy dose ( 40-50 Gy v &gt; 50-55.8 Gy ) . Patients randomize 1 2 treatment arm 1:1 ratio . ARM I : Patients receive oxaliplatin intravenously ( IV ) 2 hour , leucovorin calcium IV 2 hour , fluorouracil IV day 1 follow fluorouracil IV continuously 46 hour day 1 2 . Treatment repeat every 2 week 12 courses* absence disease progression unacceptable toxicity . ARM II : Patients receive bevacizumab** IV 30-90 minute day 1 . Patients also receive oxaliplatin , leucovorin calcium , fluorouracil arm I* . [ Note : *Patients receive prior neoadjuvant oxaliplatin include patient protocol NSABP-R-04 receive 9 course treatment follow leucovorin calcium IV fluorouracil IV ( arm II ) without ( arm I ) bevacizumab 3 course . ] [ Note : **Patients longer receive bevacizumab 4/29/2009 accrual terminate due slow accrual study ) ] Patients complete 10-15 minute questionnaire bowel function randomization , end treatment , 12 month post-treatment annually 5 year post-treatment . After completion study treatment , patient follow periodically approximately 10 year . PROJECTED ACCRUAL : 2100 patient</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Histologically confirm adenocarcinoma rectum meet 1 follow clinical ( e.g. , neoadjuvant therapy ) pathologic stag criterion : T3 , N+ , M0 T3 , N0 , M0 T4 , N0 , M0 Any T , N12 , M0 T4 , N02 , M0 disease must meet 1 follow criterion : Clinically fix tumor rectal examination tumor adherent pelvic sidewall sacrum Hydronephrosis Computed Tomography ( CT ) scan Intravenous Pyelogram ( IVP ) Ureteric bladder invasion document cystoscopy cytology biopsy Invasion prostate Vaginal uterine involvement Must undergone complete tumor resection &gt; = 28 day ago able begin treatment day 56 Must undergone concurrent neoadjuvant chemoradiotherapy* NOTE : *Neoadjuvant chemoradiotherapy receive protocol NSABPR04 allow provide met criterion Must undergone prior radiotherapy 4055.8 Gy** AND receive 1 follow chemotherapy regimen : Continuous infusion fluorouracil without oxaliplatin ; fluorouracil leucovorin calcium Capecitabine without oxaliplatin ; capecitabine without oxaliplatin OR continuous infusion fluorouracil without oxaliplatin receive protocol NSABPR04 NOTE : **Intensitymodulated radiotherapy allow ECOG performance status 01 Platelet count &gt; = 100,000/mm^3 Absolute granulocyte count &gt; = 1,500/mm^3 Bilirubin normal ( unless chronic grade 1 bilirubin elevation due Gilbert 's disease similar syndrome due slow conjugation bilirubin ) Alkaline phosphatase ( AP ) &lt; 2.5 time upper limit normal ( ULN ) aspartate aminotransferase ( AST ) &lt; 1.5 time ULN Hepatitis B C negative ( patient AP &gt; normal ) unless previously vaccinate Serum creatinine = &lt; 1.5 time ULN Urine protein : creatinine ( UPC ) ratio &lt; 1.0 OR urine protein &lt; 1 g 24hour urine collection International Normalized Ratio ( INR ) = &lt; 1.5 INR &gt; 1.5 allow provide patient fulldose anticoagulant AND meet follow criterion : Inrange INR ( i.e. , 2 3 ) stable dose warfarin low molecular weight heparin No active bleed pathological condition associate high risk bleed Negative pregnancy test Fertile patient must use effective contraception least 3 month study treatment No previous concurrent malignancy except nonmelanoma skin cancer , breast cancer situ , carcinoma situ cervix , previously treat nonpelvic cancer diseasefree &gt; 5 year Patients history breast cancer ( without evidence disease ) remain hormonal therapy &gt; 5 year eligible Patients history hypertension must blood pressure &lt; 150/90 mm Hg AND stable regimen antihypertensive therapy No prior chemotherapy pelvic radiotherapy except neoadjuvant treatment current diagnosis rectal cancer Concurrent participation protocol NSABPR04 allow Pregnant nursing Evidence metastatic disease surgical/intraoperative examination Evidence metastatic disease confirm CT scan , Magnetic resonance imaging ( MRI ) , ultrasound liver chest CT scan chest xray within past 6 month Evidence tumor outside pelvis , include liver metastasis , peritoneal seeding , metastatic inguinal lymphadenopathy Concurrent major surgery Active bleeding related primary rectal tumor within past 6 month Active inflammatory bowel disease serious medical illness might limit ability patient receive protocol therapy Active gastroduodenal ulcer determine endoscopy Serious nonhealing wound , skin ulcer , bone fracture Clinically significant peripheral sensory motor neuropathy &gt; = grade 2 Nonmalignant systemic disease ( e.g. , cardiovascular , renal , hepatic ) would preclude study treatment include , limited , follow : New York Heart Association class III IV congestive heart failure Concurrent symptomatic arrhythmia Transient ischemic attack cerebrovascular accident Arterial thromboembolic event , unstable angina , myocardial infarction within past 12 month Significant peripheral vascular disease Psychiatric addictive disorder condition , opinion investigator , would preclude study requirement Significant traumatic injury within past 28 day Known allergy platinum compound Prior invasive procedure , include either follow : Major surgical procedure open biopsy within past 28 day Core biopsy minor procedure , except placement vascular access device , within past 7 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Rectal cancer</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>